Literature DB >> 15243115

Clinical and microbiological analysis of bloodstream infections caused by Chryseobacterium meningosepticum in nonneonatal patients.

Pen-Yi Lin1, Chishih Chu, Lin-Hui Su, Chung-Tsui Huang, Wen-Ya Chang, Cheng-Hsun Chiu.   

Abstract

Chryseobacterium meningosepticum bloodstream infections in 11 nonneonatal patients were reported. More than half of the infections were community acquired. PCR assays indicated that the organisms produced extended-spectrum beta-lactamases as well as metallo-beta-lactamases. Genotyping showed diverse fingerprints among the isolates. Six patients survived without appropriate antibiotic treatment. Host factors are the major determinant of the outcomes of C. meningosepticum infections.

Entities:  

Mesh：

Year:  2004        PMID： 15243115      PMCID： PMC446307          DOI： 10.1128/JCM.42.7.3353-3355.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  18 in total

1.  Studies on a group of previously unclassified bacteria associated with meningitis in infants.

Authors:  E O KING
Journal:  Am J Clin Pathol       Date:  1959-03       Impact factor: 2.493

2.  Subacute bacterial endocarditis due to Flavobacterium meningosepticum.

Authors:  S Werthamer; M Weiner
Journal:  Am J Clin Pathol       Date:  1972-03       Impact factor: 2.493

3.  ICU-acquired pneumonia due to Flavobacterium meningosepticum.

Authors:  D Teres
Journal:  JAMA       Date:  1974-05-06       Impact factor: 56.272

4.  Flavobacterium meningosepticum meningitis in a newborn infant. Treatment with intraventricular erythromycin.

Authors:  E G Maderazo; H P Bassaris; R Quintiliani
Journal:  J Pediatr       Date:  1974-11       Impact factor: 4.406

5.  Vancomycin therapy of bacterial meningitis.

Authors:  H B Hawley; D W Gump
Journal:  Am J Dis Child       Date:  1973-08

6.  Flavobacterium meningosepticum infection: an epidemiological study in a newborn nursery.

Authors:  M L Thong; S D Puthucheary; E L Lee
Journal:  J Clin Pathol       Date:  1981-04       Impact factor: 3.411

7.  Molecular investigation of two clusters of hospital-acquired bacteraemia caused by multi-resistant Klebsiella pneumoniae using pulsed-field gel electrophoresis and in frequent restriction site PCR. Infection Control Group.

Authors:  L H Su; H S Leu; Y P Chiu; J H Chia; A J Kuo; C F Sun; T Y Lin; T L Wu
Journal:  J Hosp Infect       Date:  2000-10       Impact factor: 3.926

8.  Genetic-biochemical analysis and distribution of the Ambler class A beta-lactamase CME-2, responsible for extended-spectrum cephalosporin resistance in Chryseobacterium (Flavobacterium) meningosepticum.

Authors:  S Bellais; L Poirel; T Naas; D Girlich; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

9.  Comparative in-vitro activity of ciprofloxacin against non-fermenters.

Authors:  M O Husson; D Izard; L Bouillet; H Leclerc
Journal:  J Antimicrob Chemother       Date:  1985-04       Impact factor: 5.790

10.  Atypical Chryseobacterium meningosepticum and meningitis and sepsis in newborns and the immunocompromised, Taiwan.

Authors:  C H Chiu; M Waddingdon; D Greenberg; P C Schreckenberger; A M Carnahan
Journal:  Emerg Infect Dis       Date:  2000 Sep-Oct       Impact factor: 6.883
View more
  23 in total

1.  Community-acquired meningitis and sepsis caused by Chryseobacterium meningosepticum in a patient diagnosed with thalassemia major.

Authors:  Nisel Ozkalay; Murat Anil; Neval Agus; Mehmet Helvaci; Seral Sirti
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

2.  Occurrence of antimicrobial resistance genes sul and dfrA12 in hospital environmental isolates of Elizabethkingia meningoseptica.

Authors:  Xiaobing Jiang; Dapeng Wang; Yuxiao Wang; He Yan; Lei Shi; Lijun Zhou
Journal:  World J Microbiol Biotechnol       Date:  2012-07-10       Impact factor: 3.312

3.  Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1999-2006.

Authors:  M-S Hsu; C-H Liao; Y-T Huang; C-Y Liu; C-J Yang; K-L Kao; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-03       Impact factor: 3.267

Review 4.  Fatal case of community-acquired bacteremia and necrotizing fasciitis caused by Chryseobacterium meningosepticum: case report and review of the literature.

Authors:  Ching-Chi Lee; Po-Lin Chen; Li-Rong Wang; Hsin-Chun Lee; Chia-Ming Chang; Nan-Yao Lee; Chi-Jung Wu; Hsin-I Shih; Wen-Chien Ko
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

5.  A Chryseobacterium meningosepticum colonization outbreak in a neonatal intensive care unit.

Authors:  S Maraki; E Scoulica; A Manoura; N Papageorgiou; C Giannakopoulou; E Galanakis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-08-16       Impact factor: 3.267

6.  Chryseobacterium meningosepticum bacteremia in diabetic nephropathy patient on hemodialysis.

Authors:  M Dias; K Prashant; R Pai; B Scaria
Journal:  Indian J Nephrol       Date:  2010-10

7.  Elizabethkingia meningosepticum : An Emerging Cause of Septicemia in Critically III Patients.

Authors:  Smita Sarma; Navin Kumar; Arun Jha; Usha Baveja; Sunil Sharma
Journal:  J Lab Physicians       Date:  2011-01

8.  Neonatal Meningitis by Multidrug Resistant Elizabethkingia meningosepticum Identified by 16S Ribosomal RNA Gene Sequencing.

Authors:  V V Shailaja; Ashok Kumar Reddy; M Alimelu; L N R Sadanand
Journal:  Int J Pediatr       Date:  2014-02-09

9.  Elizabethkingia meningoseptica bacteremia in immunocompromised hosts: The first case series from India.

Authors:  Abdul Ghafur; P R Vidyalakshmi; K Priyadarshini; Jose M Easow; Revathi Raj; T Raja
Journal:  South Asian J Cancer       Date:  2013-10

10.  Elizabethkingia in Children: A Comprehensive Review of Symptomatic Cases Reported From 1944 to 2017.

Authors:  Eric J Dziuban; Jessica L Franks; Marvin So; Georgina Peacock; David D Blaney
Journal:  Clin Infect Dis       Date:  2018-06-18       Impact factor: 20.999
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.